Business context and reporting period
Rockwell Medical Technologies, Inc. manufactures and sells hemodialysis concentrates and related products, primarily in the United States, and is developing renal drug therapies. This unaudited Form 10-Q covers the quarter and six months ended June 30, 2011; comparisons are with the same 2010 periods.
Financial performance and position
- Revenue: Second-quarter sales were $11.8 million, down 23.9% from $15.5 million. First-half sales were $25.1 million, down 17.7% from $30.5 million.
- Profitability: Second-quarter gross profit was $1.1 million, versus $2.8 million; gross margin fell to 9.1% from 17.9%. First-half gross profit was $2.7 million, versus $5.1 million, with gross margin of approximately 10.9% versus 16.7%. Net loss was $4.5 million for Q2, compared with net income of $117,000; first-half net loss was $7.5 million, versus a $277,000 loss. Diluted loss per share was $0.26 for Q2 and $0.43 for the first half.
- Expenses: Research and product development expense rose to $3.3 million in Q2 and $5.7 million in the first half, from $0.4 million and $1.0 million, respectively, primarily reflecting Phase III SFP clinical trials. First-half SG&A was $4.6 million, up 4.6%; equity compensation was a significant noncash expense.
- Cash flow: First-half operating cash use was $5.0 million, compared with $1.7 million provided in 2010. Investing activities used $0.4 million; financing provided $2.4 million, primarily from exercises of warrants and options. Cash declined $2.9 million to $9.3 million.
- Liquidity and debt: At June 30, cash and cash equivalents were $9.3 million and available-for-sale investments were $12.1 million, totaling $21.5 million. Current assets were $30.3 million versus current liabilities of $6.4 million. Capitalized lease obligations totaled approximately $16,000; the filing reports no significant borrowing balance.
- Equity: Shareholders’ equity was $27.7 million, down from $30.5 million at year-end 2010. Shares issued and outstanding increased to 18.1 million from 17.5 million.
Material changes versus the prior period
- Lower international sales—especially reduced orders from one distributor—accounted for most of the sales decline. First-half international sales fell $4.3 million; domestic sales fell $1.1 million.
- Higher fuel, material, and labor costs and lower sales volumes compressed gross profit. Management attributed approximately $1.0 million of the first-half gross-profit decline to inflationary costs and $1.1 million to lower sales volume.
- Customers’ conversion to Dri-Sate dry acid concentrate increased its share of acid concentrate equivalent gallons to 56% from 44%. The product lowers customers’ cost per treatment and reduces company sales, while reducing shipping costs.
- Phase III SFP trials drove the substantial increase in research and development spending and contributed to the larger net loss and operating cash use.
Outlook, commentary, and risks
- Management expected current and prospective cash resources to fund SFP testing, FDA approval work, other anticipated R&D, and ordinary operating needs through 2011 and 2012. It expected positive operating cash flow in 2011 excluding R&D expenses and noted potential cash proceeds from warrants. These are forward-looking expectations, not guarantees.
- Management anticipated higher R&D spending in 2011 as Phase III clinical work progressed. It warned that additional testing, slower-than-expected core cash generation, or expansion plans could require additional financing or development partnerships.
- The largest international distributor placed no Q2 2011 orders and was not expected to order during the remainder of 2011. International orders may fluctuate or not recur.
- In July 2011, after the reporting period, the company acquired U.S. rights to manufacture and market a generic injectable Calcitriol product. It anticipated regulatory approval around mid-2012; sales impact was not yet assessable, and management said the purchase would not materially affect liquidity or capital resources.
- Key risks include dependence on a significant customer, concentrated and competitive markets, gross-margin pressure, FDA and clinical-trial uncertainty for SFP, healthcare funding and regulatory changes, and the possibility that international orders do not recur. The company stated there were no material changes to the risk factors in its 2010 Form 10-K.
- Management reported disclosure controls were effective at a reasonable-assurance level and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the international distributor’s order pause and domestic customer/product mix changes persist.
- Phase III SFP trial progress, spending, timing, and FDA approval requirements, including the company’s cash sufficiency assumptions.
- Whether fuel, material, and labor costs or competitive pricing further pressure gross margins.
- Potential cash proceeds from outstanding warrants and options, and any resulting share dilution.
- Regulatory progress and commercial prospects for Calcitriol, while distinguishing this post-quarter development from reported-period results.